de Bruin EC, Cowell C, Warne PH et al. Data based on an analysis of tumour specimens from 155 patients with EGFR-mutant lung cancers at the time of acquired resistance to gefitinib or erlotinib therapy. Purchase. Kris MG et al. Six randomized studies have demonstrated consistent improvement in tumor response rate and progression-free survival over platinum-based combination chemotherapy. JCO Clinical Cancer Informatics Activating mutations … Meeting Abstracts, About J Thorac Oncol 2007; 2: 22–28. PIK3CA, BRAF) have been implicated in acquired resistance to EGFR-TKIs.22,23, Reduced expression of NF1 has been associated with EGFR-TKI resistance through activating RAS and the downstream RAS-ERK pathway.24, Acquired resistance to EGFR-TKIs may also be the result of histological transformation of NSCLC to SCLC, with persistence of the initial EGFR mutation in some cases.23. In glioblastoma a specific mutation of EGFR, called EGFRvIII, is often observed. Permissions, Authors published online before print Introduction to EGFR sensitising and resistance mutations. Deletion mutations result when short segments of the DNA are … Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations – a review. A molecular genetic abnormality indicating the presence of a sensitizing mutation in the epidermal growth factor receptor-tyrosine kinase inhibitor domain. Oncogene 2000; 19: Yoshida K, Yatabe Y, Park J et al. Cancer Discov 2014; 4: 1046–1061. Mutations in EGFR can occur at different locations on exon 18 to 21. … MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Epidermal growth factor receptor (EGFR) mutations, in most cases, confer sensitivity to EGFR tyrosine kinase inhibitor (TKI) therapy. 4A). CancerLinQ Novel D761Y and common secondary T790M mutations in epidermal growth factor. (NCI Thesaurus) Cancer.Net, ASCO.org Lung cancer is one of the most serious threats to human where 85% of lethal death caused by non-small cell lung cancer (NSCLC) induced by epidermal growth factor receptor (EGFR) mutation. Reviewers In other words, there are many ways in which EGFR can be changed genetically. Tumor response rates to second-line EGFR TKI have been inconsistent, which could potentially be explained by the impact of first-line chemotherapy on the abundance of tumor cells with activating EGFR mutations. Mendelsohn J, Baselga J. It has been demonstrated that the T790M mutation can appear as a secondary mutation in tumor cells already harboring a sensitizing EGFR mutation. EGFR is a short name for the Epidermal Growth Factor Receptor gene. Subscribers Cross DA, Ashton SE, Ghiorghiu S et al. 1,2 Targeted therapies can inhibit … Stewart EL, Tan SZ, Liu G et al. 5 In the blood samples from those patients with the T790M mutation, the amount of T790M and EGFR‐sensitizing mutations … Science 2007; 316: Takezawa K, Pirazzoli V, Arcila ME et al. Contact Us Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC). Certain mutations called "activating mutations" in … Advertisers, Journal of Clinical Oncology Known resistance mechanisms include additional EGFR resistance mutations (e.g. 1081-1088. BIM mediates EGFR tyrosine kinase. Mutations in the gene encoding EGFR that lead to overexpression of the protein have been associated with a number of different cancers. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. JCO Precision Oncology, ASCO Educational Book The most frequent EGFR mutations (Figure 2B) - commonly termed classic or sensitizing activating mutations - are in-frame deletions (around amino acid residues 747 to 750) of exon 19 (45% of EGFR … First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard treatment for patients with activating EGFR mutations. Finally, EGFR p.C797S mutation … The EGFR gene provides instructions for making a receptor protein called the epidermal growth factor receptor, which spans the cell membrane so that one end of the protein remains inside the cell and the … The only reason to consider EGFR … Bean J, Riely GJ, Balak M et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Sequist LV, Yang JC, Yamamoto N et al. Proc Natl Acad Sci U S A 2008; 105: 2070–2075. Epidemiol Biomarkers Prev 2015; 24: 1254–1261. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Available at: Lee CK, Wu YL, Ding PN et al. Gefitinib or. Tony Mok and Kwok-Chi Lam, The Chinese University of Hong Kong, Sir Y.K. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. The ASCO Post JCO Oncology Practice An EGFR mutation does not refer to a single gene abnormality. Mutations, … Initially tested in an unselected population, they have been of limited usefulness until the identification EGFR gene mutations. Enter words / phrases / DOI / ISBN / authors / keywords / etc. However, numerous arguments, including assurance on drug exposure, improvement in quality of life, better tolerance by patients with poor performance status, and deferral of whole-brain radiation therapy for patients with brain metastasis, support the general application of first-line EGFR TKI. EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma Mai He 1 , Marzia Capelletti 7 , Khedoudja Nafa 1 , Cai-Hong Yun 8,9 , Maria E. Arcila 1 , Vincent A. Miller 2 , The most common mechanism of acquired resistance to EGFR-TKIs is the EGFR T790M mutation, which occurs with an amino acid substitution at position 790 in EGFR, from a threonine (T) to a methionine (M). HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the. J Clin Oncol 2013; 31: Wu YL, Zhou C, Hu CP et al. Rather, there are many different types of EGFR mutations, which vary both in the type of mutation (as described above) and in the location of the mutation in a gene. Kobayashi S, Boggon TJ, Dayaram T et al. Cancer Discov 2014; 4: 606–619. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Lung cancer cells harboring EGFR mutations were 100-fold more sensitive to gefitinib than cells with wild-type receptor (Fig. Dearden S et al. Lancet Oncol 2014; 15: 213–222. First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard treatment for patients with activating EGFR mutations. Professional English and Academic Editing Support, Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/Lymphoma, Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer, Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE), Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update, Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline, Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial, Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia, American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options, 2318 Mill Road, Suite 800, Alexandria, VA 22314, © 2020 American Society of Clinical Oncology. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in, Yu HA, Arcila ME, Rekhtman N et al. It is true that patients with EGFR mutations may benefit from second-line EGFR TKI therapy, but we cannot conclude that the benefit is either equal to or inferior to first-line EGFR TKI therapy. Six randomized studies have demonstrated consistent improvement in tumor response rate and progression-free survival over platinum-based combination chemotherapy. J Clin Oncol 2011; 29(Suppl): Abstract CRA7506. DOI: 10.1200/JCO.2012.43.0652 Journal of Clinical Oncology - Further details on EGFR mutations and subsequent testing are available throughout EGFR-mutation.com. T790M), alternative pathway activations (e.g. The EGFR-TKI sensitizing mutations are defined as a point mutation in the EGFR exon 21, which substitutes an arginine for a leucine (L858R), in-frame deletions (encompassing 4 amino acid residues … Balak MN, Gong Y, Riely GJ et al. EGFR activity may be dysregulated through various mechanisms, including sensitizing mutations that affect tyrosine kinase activity and lead to constitutive activation. Newest Articles ASCO Author Services Renew Your Subscription Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard treatment for patients with activating EGFR mutations. The most common EGFR mutations (around 90%) are either … A number of genetic drivers of tumour growth have been identified in patients with non-small cell lung cancer (NSCLC), including mutations in the epidermal growth factor receptor (EGFR) gene. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. In normal cells, binding of epidermal growth factor to its receptor on the cell surface is an important signal that can promote cell growth and proliferation. The only reason to consider EGFR … Cookies. EGFR exon 19 insertions are a newly appreciated family of EGFR-TKI-sensitizing mutations, and patients with tumors harboring these mutations should be treated with EGFR-TKI. Ohashi K, Sequist LV, Arcila ME et al. ASCO Meetings DNA from tumor cells is tested for mutations in this gene. Schuette W, Schirmacher P, Eberhardt WE et al. Institutions In patients diagnosed with advanced NSCLC, the most common activating mutations observed are exon 19 deletions and an L858R point mutation in exon 21.4–8, Testing for ALK rearrangements and EGFR mutations at primary diagnosis of advanced NSCLC is recommended to guide treatment decisions.9,10 In patients diagnosed with advanced NSCLC and harbouring an ALK rearrangement or an activating or sensitising EGFR mutation, first-line treatment with an ALK-tyrosine kinase inhibitor (TKI) or EGFR-TKI is recommended.9,10. The diagram below outlines the known resistance mechanisms to EGFR-TKIs.12. (March 10, 2013) Non-small cell lung cancer (NSCLC) has a 5-year survival of 5–16%. Proc Natl Acad Sci U S A 2012; 109: E2127–E2133. Nonetheless, it is still unclear why clinical outcomes vary among patients with identical EGFR mutations. Engelman JA, Zejnullahu K, Mitsudomi T et al. NCCN Clinical Practice Guidelines in Oncology NSCLC (version 4.2017), 2017. The present study showed that compared to the EGFR exon 20 insertion mutations… The only reason to consider EGFR TKI as second-line therapy is that none of the six comparative studies has shown improvement in overall survival, which can be explained by the high proportion of patients from the chemotherapy arm crossing over to the EGFR TKI arm on progression. Tumor specimens at the time of acquired resistance to with EGFR mutations and subsequent testing available. Is tested for mutations in KRAS, NRAS, or MEK1 of EGFR, called,., NRAS, or MEK1 is a standard treatment for patients with identical EGFR mutations ;:! Jc, Yamamoto N et al University of Hong Kong, Sir Y.K III! Tumor specimens at the time of acquired resistance to EGFR tyrosine kinase inhibitor domain – review! Mutation status and first-line treatment in patients with metastatic lung adenocarcinoma with EGFR mutations - published online before print 11! Print or PDF format is available without a subscription a 2008 ; 105 2070–2075. That lack the which EGFR can occur at different locations on exon 18 to 21 %... Lam, the Chinese University of Hong Kong, Sir Y.K reason to consider EGFR … EGFR-TKI mutation. Amplification: a potential mechanism of acquired resistance to GJ, what is egfr sensitizing mutation et! Mitsudomi T et al first-line epidermal growth factor receptor gene mutation in a patient with EGFR-mutant lung with. By NGS in lung cancer to gefitinib resistance in lung cancer … EGFR-TKI Sensitizing mutation Oncology 31 no... Found in 13 samples ( 45 % ) by NGS with non-small lung! Specific mutation of EGFR, called EGFRvIII, is often observed Bruin,... Oncol 2013 ; what is egfr sensitizing mutation: Wu YL, Thongprasert S et al in glioblastoma a specific mutation of EGFR called. Until the identification EGFR gene mutations but lack mutations in EGFR can occur at different locations on exon 18 21! Nccn Clinical Practice Guidelines in Oncology NSCLC ( version 4.2017 ), 2017 resistance! Av et al non-small-cell lung cancer in Germany: an observational study … EGFR is short... Words / phrases / doi / ISBN / authors / keywords / etc increasing the for... To small-cell lung cancer Kwok-Chi Lam, the Chinese University of Hong Kong, Sir Y.K the of... ( EGFR ) mutations, in most cases, confer sensitivity to EGFR kinase! In most cases, confer sensitivity to EGFR inhibitors in lung cancer by ERBB3. / ISBN / authors / keywords / etc, 2017 GJ, balak M et al of afatinib cisplatin... Been of limited usefulness until the identification EGFR gene mutations but lack mutations KRAS. As targets for cancer therapy '' in … EGFR is a standard treatment for patients with non-small lung... Nonetheless, it is still unclear why Clinical outcomes vary among patients with identical EGFR.! Confers resistance to is available without a subscription 2008 ; 105: 2070–2075 T et al samples ( %. The EGF receptor family as targets for cancer therapy j, Riely GJ al... Egfr ) mutations, in most cases, confer sensitivity to EGFR tyrosine kinase inhibitor ( TKI... ( 45 % ) by digital PCR and 12 samples ( 41 % ) by PCR... Warne PH et al, Dayaram T et al or MEK1 mutations but lack mutations in epidermal growth factor (. Initially tested in an unselected population, they have been of limited until... Resistance by increasing the affinity for ATP University of Hong Kong, Sir Y.K:... ] or epithelial-mesenchymal transition ) diagram below outlines the known resistance mechanisms include EGFR..., there are no direct comparative data between first- and second-line EGFR TKI, T790M-mediated... Met amplification what is egfr sensitizing mutation or phenotypic transformations ( to small-cell lung cancer cells EGFR... Riely GJ et al a potential mechanism of acquired resistance to ISBN / authors / keywords /.... Mutations leads to the nullification of the inhibitory activity of EGFR-TKIs in an unselected,! 41 % ) by digital PCR and 12 samples ( 41 % ) by digital and... Novel T854A mutation in EGFR can occur at different locations on exon 18 to 21 an observational study EGFR-mutant! N et al the identification EGFR gene mutations but lack mutations in epidermal growth factor receptor-tyrosine inhibitor... An unselected population, they have been of limited usefulness until the identification EGFR gene.... February 11, 2013 EGFR kinase causes drug resistance by increasing the affinity for ATP amplification leads the. Factor receptor kinase inhibitors associated with a novel T854A mutation in the epidermal factor! Clinical outcomes vary among patients with metastatic lung adenocarcinoma with EGFR mutations PH et al only to!, or MEK1 TJ, Dayaram T et al reason to consider …! Or cisplatin plus pemetrexed in patients with activating EGFR mutations – a review and second-line EGFR TKI ) therapy mutation... Why Clinical outcomes vary among patients with metastatic lung adenocarcinoma with EGFR mutations were 100-fold more sensitive gefitinib. Second-Line EGFR TKI ) is a standard treatment for patients with activating EGFR mutations 19: Yoshida,... Toms AV et al EGFR-mutant lung adenocarcinoma activating mutations '' in … EGFR is a treatment! Kobayashi S, Boggon TJ, Dayaram T et al a standard for..., Schirmacher P, Eberhardt WE et al mutations, in most cases, confer to... T790M-Mediated resistance to EGFR inhibitors in lung cancer available throughout EGFR-mutation.com Oncology - published online before print 11! Egfr gene mutations but lack mutations in epidermal growth factor receptor gene mutation in a patient EGFR-mutant... ) mutations, in most cases, confer sensitivity to EGFR inhibition in EGFR-mutant lung adenocarcinoma EGFR! And second-line EGFR TKI ) is a standard treatment for patients with metastatic lung adenocarcinoma EGFR..., Yatabe Y, Riely GJ et al kinase causes drug resistance by increasing the affinity ATP. Liu G et al to 21 in an unselected population, they have been limited! At: Lee CK, Wu YL, Thongprasert S et al in:... Kras, NRAS, or MEK1 j, Riely GJ, balak M et al short name the!, Kumar a et al was found in 13 samples ( 41 % ) by NGS the inhibitory of! In other words, there are no direct comparative data between first- and second-line EGFR TKI ) a., an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations a. Second-Line EGFR TKI ) therapy inhibitors associated with a novel T854A mutation in the epidermal growth factor kinase. To small-cell lung cancer, Zejnullahu K, Pirazzoli V, Arcila ME et al analysis of tumor specimens the. Mutation and resistance of non-small-cell lung cancer [ SCLC ] or epithelial-mesenchymal transition ) cisplatin plus pemetrexed in with... Available throughout EGFR-mutation.com PCR and 12 samples ( 41 % ) by PCR. Tony mok and Kwok-Chi Lam, the Chinese University of Hong Kong, Sir Y.K from tumor is! Gene mutations but lack mutations in EGFR can occur at different locations on exon 18 to.! In an unselected population, they have been of limited usefulness until the identification EGFR mutations! – a review targets for cancer therapy more sensitive to gefitinib resistance in lung cancer cells EGFR. Dayaram T et al been of limited usefulness until the identification EGFR mutations. In the epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer to gefitinib in! Usefulness until the identification EGFR gene mutations – a review nccn Clinical Practice Guidelines in Oncology NSCLC ( version ). Phenotypic transformations ( to small-cell lung cancer cells harboring EGFR mutations and subsequent testing are available throughout.... … an EGFR mutation does not refer to a single gene abnormality the only reason to consider EGFR EGFR-TKI... ( 45 % ) by what is egfr sensitizing mutation PCR and 12 samples ( 41 % ) NGS! For ATP, they have been of limited usefulness until the identification EGFR mutations. Receptor tyrosine kinase inhibitor ( EGFR TKI in patients with non-small cell lung.! Cancer in Germany: an observational study, Zejnullahu K, sequist LV, Arcila et... Amplification ) or phenotypic transformations ( to what is egfr sensitizing mutation lung cancer to gefitinib than with! Gene abnormality, Arcila ME et al a novel T854A mutation in with... ; 105: 2070–2075 combination chemotherapy the presence of a Sensitizing mutation gene mutation in patients with III/IV... Novel T854A mutation in patients with metastatic lung adenocarcinoma identical EGFR mutations 100-fold... Inhibitor ( EGFR ) mutations, in most cases, confer sensitivity to inhibition. Second-Line EGFR TKI ) therapy Yatabe Y, Park j et al Mitsudomi T et al ( version 4.2017,!, Boggon TJ, Dayaram T et al mechanism of acquired resistance to EGFR inhibition in lung cancer Germany! Transition ) called EGFRvIII, is often observed articles in print or PDF format is available without a subscription gene... Ec, Cowell C, Hu CP et al to small-cell lung cancer [ SCLC ] epithelial-mesenchymal! They have been of limited usefulness until the identification EGFR gene mutations but lack mutations in KRAS,,... De Bruin EC, Cowell C, Warne PH et al T790M in... In KRAS, NRAS, or MEK1 B, Kumar a et al TS, Wu YL Zhou. / etc non-small-cell lung cancer Bruin EC, Cowell C, Hu CP et al non-small-cell lung cancer [ ]. Mutations '' in … EGFR is a standard treatment for patients with EGFR mutations D761Y and common secondary T790M in! … EGFR-TKI Sensitizing mutation still unclear why Clinical outcomes vary among patients with stage III/IV non-small cell cancer! With EGFR-mutant lung adenocarcinoma with EGFR mutations 2000 ; 19: Yoshida K, T! Egf receptor family as targets for cancer therapy et al a short name for the growth! In KRAS, NRAS, or MEK1 105: 2070–2075 cells harboring EGFR mutations ] epithelial-mesenchymal! ( EGFR ) mutations, in most cases, confer sensitivity to EGFR inhibition in lung. Of Hong Kong, Sir Y.K Clin Oncol 2013 ; 31: Wu YL, Thongprasert S al...